Successes, lessons learned and recommendations for the future: Experiences from the first year of Ontario's...

Area of Science:

• Public Health
• Pediatrics
• Health Systems Research

Background:

• Ontario launched its first infant respiratory syncytial virus (RSV) prophylaxis program using nirsevimab.
• A prior meeting in June 2024 aimed to establish recommendations for a universal infant prophylaxis program.

Purpose of the Study:

• To evaluate the successes and identify barriers of the initial nirsevimab program in Ontario.
• To refine recommendations for enhancing future RSV prophylaxis programs for infants.

Main Methods:

• A panel of healthcare providers involved in the nirsevimab program convened post-RSV season.
• A modified World Health Organization health systems analytical framework guided the discussion.
• Key programmatic areas included governance, funding, logistics, awareness, and surveillance.

Main Results:

• Consensus was reached on updated recommendations for Ontario's nirsevimab program.
• The recommendations address identified successes and barriers to nirsevimab uptake.
• Focus areas include equitable access, optimal program uptake, and enhanced infant protection against RSV.

Conclusions:

• The refined recommendations aim to improve the success of nirsevimab administration for future RSV seasons.
• Ensuring equitable access and optimal uptake are critical for maximizing infant protection against RSV.
• Continuous program evaluation and adaptation are essential for effective public health interventions.